Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Dig Dis Sci. 2009 Jun 9;55(5):1396–1405. doi: 10.1007/s10620-009-0839-8

Table 1.

Characteristics, symptoms, and treatment of ipilimumab recipients who developed diarrhea.

Patient Cancer1 Age/
Sex		 Therapy Prior to Ipilimumab #doses
ipilimumab		 Signs and symptoms Treatment of colitis2
Hormone/
cytokine3 		cytotoxic
chemo		 Irradiation Diarrhea
(max)		 Abd.
pain		 Rectal
blood		 Initial
therapy		 Secondary
therapies		 Outcome
#1 Mel 38/F Yes Yes Axilla 2 Grade 2 No No B None Resolution
#2 Mel 58/M Yes Yes None 8 Grade 2 No No B None Resolution
#3 Mel 48/F Yes No None 3 Grade 3 No No B 2mg/kg/d G, T Resolution
#4 Mel 64/M No Yes Brain 4 Grade 3 No Yes 2mg/kg/d G None Resolution
#5 Prost 81/M Yes No None 2 Grade 3 No No 1mg/kg/d G None Resolution
#6 Mel 64/F No Yes None 1 Grade 3 Yes No 2mg/kg/d G None Improvement4
#7 Mel 68/M No Yes None 2 Grade 3 Yes No 2mg/kg/d G I Resolution
#8 Prost 62/M Yes Yes Pelvic 2 Grade 3 No No 1mg/kg/d G I, T Improvement
but relapse off
therapy
#9 Prost 52/M Yes Yes Pelvic 1 Grade 3 Yes Yes 2mg/kg/d G I, T, R Persistent
symptoms5
1

Mel=melanoma. Prost=Prostate cancer.

2

B=budesonide, G=glucocorticoids (prednisone or methylprednisolone), I=infliximab, T=tacrolimus, R=rapamycin

3

Hormonal therapy was used exclusively in prostate cancer patients. Cytokine therapy was used exclusively in patients with melanoma.

4

Patient died of cancer before completing a course of prednisone

5

Patient died from opportunistic Aspergillus infection